MLR Content Management: What Happens After Approval

Last updated August 2026.

Ask anyone who has shepherded a piece through medical, legal, and regulatory review what the hard part is, and they will point to the front end: the drafting, the annotation, the reference pack, the back and forth until every claim lines up with the label. That work is real, and it is expensive. But it hides a quieter problem. The day a piece clears MLR is treated as the finish line, when it is actually the start of a lifecycle that most systems stop watching. What happens to that content afterward, the post-approval content lifecycle, is the central weakness in how MLR content management works in practice, and it is worth naming as a systems problem rather than a string of one off mistakes.

What actually happens to content after MLR approval?

Approval answers exactly one question: is this piece acceptable to distribute today? It does not answer the questions that matter for the rest of that piece's time in circulation. Is it still current? When does it expire? Which version is the approved one, and which are the near identical copies sitting in inboxes and shared drives? Who owns it now that the reviewer has moved on? In most organizations the honest answer is that no single system holds all four of those facts reliably. Status, expiration, versioning, and ownership drift apart the moment the approval stamp lands.

If that sounds overstated, consider that the regulator responsible for overseeing this content wrestles with the same problem. The Government Accountability Office found that FDA reviews only a small portion of the direct to consumer materials it receives and does not document whether a particular material was reviewed. Because the agency does not track information on its reviews, GAO concluded it cannot determine whether a particular material has been reviewed at all (Government Accountability Office, GAO-07-54, 2006). A follow-up GAO review in 2008 found the same gap persisted: FDA officials confirmed the agency still did not track whether a particular material had been reviewed (Government Accountability Office, GAO-08-758T, 2008). If the body that writes the rules cannot reliably say which material has what status, a field team without a real system has no chance.

Volume is part of why. In 2005 alone, FDA received 4,600 final DTC materials excluding the internet, another 6,168 final internet materials, and 4,690 final consumer directed materials, with the total number of promotional pieces submitted having almost doubled since the agency formed its review group in 2002 (Government Accountability Office, GAO-07-54, 2006). Content does not arrive in a trickle a person can hold in their head. It arrives in floods, and floods require systems built for the whole lifecycle, not just the intake moment.

Why does the post-approval gap show up in almost every system?

The gap is structural, not accidental. Most content tools are built around the approval event because that is the moment with a clear owner, a clear deadline, and a clear definition of done. The lifecycle after approval has none of those. Nobody is assigned to notice that a claim went stale, that a referenced study was superseded, or that a piece quietly passed its use by date while still circulating. That gap is the post-approval content lifecycle nobody owns.

Regulatory design reinforces the habit. Under 21 CFR 314.81(b)(3)(i), applicants must submit specimens of promotional labeling and advertising to FDA on Form FDA-2253 at the time of initial dissemination, with the product current professional labeling (21 CFR 314.81, Cornell Law LII, accessed 2026). Read that carefully. It is a submit at launch obligation, not a pre approval gate. Most promotional pieces are never cleared by FDA before they go out, which means responsibility for keeping a piece accurate across its life sits entirely with the manufacturer. In practice, that means it sits with your systems and your people.

And accuracy is not a one time property. 21 CFR 202.1 requires prescription drug advertising to present a true statement that includes a brief summary of side effects, contraindications, and effectiveness, and to maintain fair balance. An ad is misleading if it presents effectiveness in greater scope, depth, or detail than risk, or if risk information lacks prominence and readability reasonably comparable to the efficacy claims, down to typography, layout, and contrast (21 CFR 202.1, Cornell Law LII, accessed 2026). Fair balance can degrade without a single word changing. A piece gets excerpted into a shorter format, a safety section gets clipped in a resize, an approved visual gets reused in a context it was never balanced for. A system that only records that the original passed review will never catch any of that.

When post-approval oversight does catch up, it lags badly. Of the 19 regulatory letters FDA issued citing violative DTC materials in 2004 and 2005, the letters came on average eight months after the material was first disseminated, and by the time they arrived companies had already discontinued more than half of the cited materials (Government Accountability Office, GAO-07-54, 2006). The content had lived its entire life and gone quiet before anyone formally flagged it. That is the shape of the problem in miniature: tracking and enforcement both arrive after the fact.

Does a bigger platform mean better compliance precision?

The revenue enablement category is consolidating, and its own vendors are the ones saying so. In February 2026, Highspot and Seismic announced a definitive agreement to merge, and the deal closed on August 18, 2026. The combined company now operates under the Seismic brand, with Permira as controlling shareholder and no financial terms disclosed (Highspot and Seismic merger announcements, 2026). The DOJ's Antitrust Division closed its investigation into the deal the next day, after what it called a "targeted review" (U.S. Department of Justice, Antitrust Division, August 19, 2026). Showpad and Bigtincan have combined (Forrester, 2026). Forrester, which examined 18 vendors in its Q1 2026 landscape, describes a market that is consolidating and product differentiation that is diminishing as the category matures (Forrester, Eric Zines, 2026). Read that last point plainly: the largest platforms are becoming more alike as they get bigger. Scale still buys real things, uptime, breadth, an integration for every adjacent tool. It does not buy product-specific compliance precision, and a market that is openly converging is not a market quietly solving healthcare's post-approval problem on your behalf.

Precision is where the general platform assumption breaks. Take accelerated approval. Under 21 CFR 314.550, applicants for accelerated approval drugs must submit all promotional materials to FDA during the pre approval review period for the first 120 days after approval, and after that window materials must be submitted at least 30 days before intended use (21 CFR 314.550, Cornell Law LII, accessed 2026). That is the opposite of the general submit at launch rule, and a generic content platform will not know your product falls under it unless someone configured that nuance deliberately. Clinical and regulatory precision is not a feature that ships in the box with size, and it does not arrive as a byproduct of a merger. A platform assembled to serve thousands of accounts across every industry has no particular reason to encode the accelerated approval calendar for your molecule. Precision has to be understood, per product, per indication, per audience.

The downstream cost of getting it wrong is not theoretical. A drug is misbranded under 21 U.S.C. 352 if its labeling is false or misleading in any particular, and distributing a misbranded drug is a prohibited act (21 U.S.C. 352, Cornell Law LII, accessed 2026). When promotional claims have outrun the approved label, the settlements have been enormous. GlaxoSmithKline paid $3 billion in 2012 to resolve unlawful and off-label promotion and related conduct (U.S. Department of Justice, 2012). Pfizer paid $2.3 billion in 2009, Johnson and Johnson $2.2 billion in 2013, and Abbott $1.5 billion in 2012, each case involving off-label promotion (U.S. Department of Justice, 2009 to 2013). The volume of promotional content behind numbers like those is easy to underestimate. The industry spent billions of dollars a year on direct-to-consumer advertising alone from 2016 through 2018 (Government Accountability Office, GAO-21-380, 2021), and every piece of it has to stay accurate for as long as it circulates. The distance between what was approved and what is actually in the field is not a filing detail. It is the exposure. Off-label promotion risk is exactly that distance, made concrete in a settlement.

Which post-approval capabilities should a buyer require?

The regulatory drivers above point to a specific set of capabilities, and each one maps to a distinct way approved content can drift out of compliance. These are worth treating as requirements to test in an evaluation, not features to admire in a demo.

Because fair balance under 21 CFR 202.1 can degrade when a piece is excerpted, resized, or reused, a buyer should require the ability to identify, on demand, which currently circulating pieces reference a given study or claim (21 CFR 202.1, Cornell Law LII, accessed 2026). When a reference is superseded, tracing every downstream piece that relied on it is what separates a catalog of past approvals from a system that can act on the change. The testable question is plain: which live pieces cite this study, and can the tool list them without a manual search?

Because the submit at launch structure of 21 CFR 314.81(b)(3)(i) leaves accuracy across a piece's entire circulation to the manufacturer, a buyer should require expiration and ownership to be maintained as live fields rather than static metadata recorded on the day of approval (21 CFR 314.81, Cornell Law LII, accessed 2026). In practice that means the system can name the current owner after the original reviewer changes roles, and can surface which pieces are approaching their review date before they lapse. Both are demonstrable in a working system rather than asserted on a slide.

And because a rep in a regulated conversation cannot wait days for clarity on whether a piece is current, a buyer should require version resolution to return one designated approved version, not simply the most recently saved file. The gap between those two behaviors is the difference between a field team acting on verified content and one working from a best guess.

Should direct clinical and regulatory answers require escalation?

Here is a standard worth holding vendors to: a rep or a compliance lead should be able to get a real, direct answer on a clinical or regulatory specific without an escalation chain. Too often the response to a pointed question, can I use this claim in this context for this audience, is a ticket, a queue, and a wait. That is a design choice, not a law of nature, and it quietly trains a field team to stop asking.

The stakes on this are rising as AI enters the workflow. Ungrounded language models are not a safe substitute for a direct, sourced answer. A Stanford study found that large language models produced hallucinations 69 to 88 percent of the time in response to specific legal queries, and hallucinated on court holdings at least 75 percent of the time (Stanford HAI RegLab, 2024). Regulatory questions share a trait with legal ones: the answer is either grounded in an authoritative source or it is worthless. A team should expect answers that cite the label, the reference, or the regulation, and it should expect them without a multi day escalation. Whether the answer comes from a knowledgeable human or a well grounded system, the standard is identical: direct, sourced, and fast.

What should you actually test in a vendor evaluation?

Turn all of this into a short exercise you can run with any vendor, regardless of size. Ask them to show you live, not on a slide. First, pull up a piece of approved content and state its current status, expiration date, approved version, and current owner in one place, with no spreadsheet on the side. Second, tell me what happens when a referenced study changes: who gets notified, and how. Third, answer a genuinely product-specific regulatory question, and let me time how long it takes to get a sourced response. If the first two are a struggle and the third becomes a ticket, you have learned more about the relationship ahead than any feature list will tell you.

The pattern this piece names, approval tracked carefully and everything after it tracked loosely, is common precisely because it stays invisible until it costs you. Naming it is the first step to buying against it, and the questions above are how you find out whether a vendor has already solved it or is quietly hoping you will not ask. A merger does not answer those questions for you, and a bigger logo on the contract does not either.

Most teams that get this right refuse to treat the lifecycle, and the direct answers that go with it, as afterthoughts. That is the premise Accent is built on. Accent is independent, it is built for the full content lifecycle rather than the approval moment, and it treats a direct, sourced answer to a clinical or regulatory question as the product rather than a favor granted after a wait. As the category consolidates and its own vendors concede that differentiation is fading, independence and provider-specific precision stop being nice to have and start being the whole point. For readers weighing what that independence looks like, this further reading on the independent alternative is one place to start. Independence and precision are what keep off-label promotion risk from becoming next year's settlement instead of this year's near miss.

Frequently asked questions

Does FDA approve promotional content before it is used?

Generally no. Under 21 CFR 314.81(b)(3)(i), most promotional materials are submitted on Form FDA-2253 at the time of initial dissemination, not before (21 CFR 314.81, Cornell Law LII, accessed 2026). The main exception is accelerated approval products, where 21 CFR 314.550 requires materials to be submitted for review during the pre approval period and, afterward, at least 30 days before intended use (21 CFR 314.550, Cornell Law LII, accessed 2026).

What makes approved content noncompliant later?

Accuracy is not permanent. Fair balance under 21 CFR 202.1 can degrade when a piece is excerpted, resized, or reused in a new context, so that risk information no longer has prominence and readability reasonably comparable to the efficacy claims (21 CFR 202.1, Cornell Law LII, accessed 2026). A referenced study can also be superseded. Clearance at launch does not guarantee compliance across the content whole life. That is the post-approval content lifecycle working against you instead of for you.

Why is post-approval tracking so hard even for large organizations?

Volume and structure. FDA itself receives more materials than it can review and does not document which ones it reviewed (Government Accountability Office, GAO-07-54, 2006). Manufacturers face the same volume without the option to skip it, and most tools are built around the approval moment rather than the lifecycle that follows.

Is a larger platform automatically safer for compliance?

Scale and precision are different things. Consolidation has produced larger vendors; Highspot and Seismic's merger closed on August 18, 2026, with the combined company operating under the Seismic brand and Permira as controlling shareholder (Highspot and Seismic merger announcements, 2026), and Forrester reports the market is consolidating while product differentiation diminishes (Forrester, Eric Zines, 2026). Larger does not mean more precise. Product-specific nuance like accelerated approval obligations still has to be configured deliberately, and size does not encode your product regulatory particulars on its own.

Sources

• U.S. Government Accountability Office, GAO-07-54, Prescription Drugs: Improvements Needed in FDA Oversight of Direct-to-Consumer Advertising (2006)
• U.S. Government Accountability Office, GAO-21-380, Prescription Drugs: Medicare Spending on Drugs with Direct-to-Consumer Advertising (2021)
• U.S. Department of Justice, Antitrust Division statement, Aug 19, 2026
• 21 CFR 314.81 (Cornell Law School Legal Information Institute, current CFR accessed 2026)
• 21 CFR 202.1 (Cornell Law School Legal Information Institute, current CFR accessed 2026)
• 21 U.S.C. 352, Federal Food, Drug, and Cosmetic Act (Cornell Law School Legal Information Institute, accessed 2026)
• 21 CFR 314.550 (Cornell Law School Legal Information Institute, current CFR accessed 2026)
• GAO-07-54 (2006)
• GAO-08-758T (2008 follow-up)
• List of largest pharmaceutical settlements, U.S. Department of Justice figures (2009 to 2013)
• Highspot, announcement of definitive agreement to merge with Seismic (2026)
• Seismic, announcement of definitive agreement to merge with Highspot (2026)
• GeekWire coverage of the merger closing
• Forrester, revenue enablement platform landscape, Q1 2026, Eric Zines (2026)
• Hallucinating Law: Legal Mistakes with Large Language Models Are Pervasive (Stanford HAI RegLab, 2024)